Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Weiwei Chen, Ph.D.

Program Director
Developmental Therapeutics Program
Preclinical Therapeutics Grants Branch
240-276-5986
|
Weiwei.chen@nih.gov

Dr. Weiwei Chen obtained her Ph.D. in molecular pharmacology from New York University, where she studied the molecular interaction between the mediator complex and the glucocorticoid receptor (GR) and the regulation of GR transcriptional activities. After graduation, she joined Genentech, Inc. to discover molecular targets important in promoting tumor angiogenesis. She also aimed to understand the molecular and functional crosstalk between tumor and tumor microenvironment with a focus on the paracrine mechanism of hedgehog signaling in ligand-dependent tumor types. Before joining PTGB, Dr. Chen served as Program Manager of the NCI Experimental Therapeutics (NExT) Program, through which extramural researchers may gain access to NCI’s cancer drug discovery and development resources. Dr. Chen's areas of interest reside in the preclinical discovery and development of pharmacological interventions to overcome cancer drug resistance and metastasis, and the impact of aging on cancer therapy development. She manages a portfolio highlighted with projects focusing on cancer target discovery and validation, proof-of-concept efficacy testing, therapy toxicity studies, and in vivo pharmacokinetics and pharmacodynamics characterization to improve the therapy of gastrointestinal cancers.

Email